About us

ENABLE-2 has built an antibacterial drug discovery platform based on the learnings from ENABLE (Innovative Medicines Initiative project, 2014-2021) with focus on the early stages of antibiotic discovery and development. ENABLE-2 is filling a gap, feeding the early pipeline of new antibiotics, to ensure a sustainable flow of new antibacterial drug candidates into the development pipeline.

ENABLE-2 is supporting the development of direct acting systemic antibacterial compounds. Potentiator molecules may also be in scope, e.g. β-lactamase inhibitors. Anti-virulence and anti-biofilm compounds are not in scope. Pathogens in scope for ENABLE-2 are E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus and E. faecium (ESKAPE pathogens).

This is ENABLE-2

Experimental platform with capabilities in chemistry, microbiology, ADME, safety and in vivo efficacy that will work with programme owners to advance their compounds towards advanced Lead status. ENABLE-2 provides nondilutive experimental support to early stage antibiotic projects.

Expert knowledge hub. The Portfolio Management Committee (PMC) of ENABLE-2 is composed of international independent experts with broad antibacterial drug discovery and development experience. They will mentor your programme and advise on challenges as well as on how to mitigate liabilities.

Supports programme owners to acquire key missing data for the PMC. If your programme does not fully meet the thresholds for entry into the ENABLE-2 platform there is a possibility of a Material Transfer Agreement (MTA) Route – a kind of pre-ENABLE-2 development package where this data could be generated.

Maintains data confidentiality. ENABLE-2 adheres to a very restrictive communication policy and will only communicate what you agree upon or what is released by yourself.

Current call

A call is now open for new antibiotic programmes. This call is open to researchers at publicly funded universities and research institutes in Europe.

Previous Calls

An initial call, open exclusively to Swedish research groups, including both academics and SMEs, was conducted October 4–31, 2021. In 2022, ENABLE-2 launched with four promising programmes.

A second call, open to Swedish research groups, including both academics and SMEs, and to publicly funded universities in Europe, was conducted December 20, 2022 to January 8, 2023.

A third call, open to Swedish research groups, including both academics and SMEs, and to publicly funded universities in Europe, was conducted April 3 to May 5, 2023.

Learn more

Contact ENABLE-2